C.R. Jackson
Biotech, healthcare, value, research analyst

Can Cempra Beat The Superbugs?

"People actually talk these days about a potential return to the "pre-antibiotic era" where we no longer have effective tools to treat serious infectious disease. Clearly, we must encourage more judicious use of these important drugs through improved infection control, rational prescribing and better patient compliance. But even if we improve these practices, resistant bacteria will continue to develop. No matter what, we need new and better drugs…and we need them now. Yet the R & D pipeline is distressingly low..."

--Margaret A. Hamburg, M.D.
Commissioner, U.S. Food and Drugs Administration (FDA)
National Press Club Luncheon, October 6, 2010.

Antibiotic-resistant bacteria, also known as "superbugs," pose a significant threat to public health. New antibiotics are not being developed...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details